Q2 EPS Estimates for Sana Biotechnology Cut by HC Wainwright

Sana Biotechnology, Inc. (NASDAQ:SANA) – Analysts at HC Wainwright cut their Q2 2026 earnings estimates for Sana Biotechnology in a research report issued on Tuesday, May 12th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.13) for the quarter, down from their prior forecast of ($0.12). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Sana Biotechnology’s FY2026 earnings at ($0.56) EPS.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01.

A number of other equities analysts have also commented on SANA. Weiss Ratings lowered shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Wedbush lifted their price target on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Rodman & Renshaw began coverage on shares of Sana Biotechnology in a research report on Monday. They set a “buy” rating and a $16.00 target price on the stock. Zacks Research lowered shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Finally, Wall Street Zen raised shares of Sana Biotechnology from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.50.

Sana Biotechnology Stock Down 1.8%

NASDAQ:SANA opened at $3.20 on Thursday. Sana Biotechnology has a 12 month low of $1.60 and a 12 month high of $6.55. The firm has a market cap of $890.53 million, a price-to-earnings ratio of -3.44 and a beta of 2.17. The company’s 50 day moving average is $3.29 and its 200-day moving average is $3.98.

Hedge Funds Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of SANA. Mercer Global Advisors Inc. ADV bought a new position in Sana Biotechnology during the third quarter worth $36,000. TD Waterhouse Canada Inc. bought a new position in Sana Biotechnology during the third quarter worth $37,000. Lyell Wealth Management LP acquired a new stake in Sana Biotechnology during the third quarter worth $37,000. Rockefeller Capital Management L.P. boosted its stake in Sana Biotechnology by 74.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after buying an additional 4,088 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Sana Biotechnology during the third quarter worth $39,000. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.